Celldex Therapeutics, Inc. (FRA:TCE2)
Germany
· Delayed Price · Currency is EUR 23.60
+1.00 (4.42%)
At close: Dec 4, 2025
Celldex Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 2.6 | 7.02 | 6.88 | 2.36 | 4.65 | 7.42 | Upgrade
|
| Revenue Growth (YoY) | -73.95% | 1.99% | 192.02% | -49.32% | -37.30% | 107.61% | Upgrade
|
| Cost of Revenue | 216.68 | 163.55 | 118.01 | 82.26 | 53.31 | 42.53 | Upgrade
|
| Gross Profit | -214.08 | -156.53 | -111.13 | -79.9 | -48.66 | -35.12 | Upgrade
|
| Selling, General & Admin | 42.16 | 38.55 | 30.91 | 27.2 | 20.49 | 14.46 | Upgrade
|
| Operating Expenses | 42.16 | 38.55 | 30.91 | 27.2 | 20.49 | 14.46 | Upgrade
|
| Operating Income | -256.24 | -195.08 | -142.04 | -107.1 | -69.15 | -49.57 | Upgrade
|
| Interest & Investment Income | 31.71 | 37.22 | 13.11 | 2.91 | 0.51 | 2.41 | Upgrade
|
| EBT Excluding Unusual Items | -224.53 | -157.86 | -128.93 | -104.19 | -68.64 | -47.17 | Upgrade
|
| Legal Settlements | - | - | -12.5 | -15 | - | - | Upgrade
|
| Other Unusual Items | - | - | - | 6.86 | 1.41 | 4.22 | Upgrade
|
| Pretax Income | -224.53 | -157.86 | -141.43 | -112.33 | -70.74 | -60.95 | Upgrade
|
| Income Tax Expense | - | - | - | - | -0.23 | -1.17 | Upgrade
|
| Net Income | -224.53 | -157.86 | -141.43 | -112.33 | -70.51 | -59.78 | Upgrade
|
| Net Income to Common | -224.53 | -157.86 | -141.43 | -112.33 | -70.51 | -59.78 | Upgrade
|
| Shares Outstanding (Basic) | 66 | 64 | 48 | 47 | 43 | 30 | Upgrade
|
| Shares Outstanding (Diluted) | 66 | 64 | 48 | 47 | 43 | 30 | Upgrade
|
| Shares Change (YoY) | 9.16% | 32.91% | 3.33% | 9.37% | 44.64% | 104.31% | Upgrade
|
| EPS (Basic) | -3.38 | -2.45 | -2.92 | -2.40 | -1.64 | -2.02 | Upgrade
|
| EPS (Diluted) | -3.38 | -2.45 | -2.92 | -2.40 | -1.64 | -2.02 | Upgrade
|
| Free Cash Flow | -181.67 | -159.7 | -109.11 | -105.56 | -62.16 | -41.96 | Upgrade
|
| Free Cash Flow Per Share | -2.74 | -2.48 | -2.25 | -2.25 | -1.45 | -1.42 | Upgrade
|
| Operating Margin | -9859.22% | -2778.89% | -2063.66% | -4543.74% | -1486.73% | -668.27% | Upgrade
|
| Profit Margin | -8639.17% | -2248.76% | -2054.76% | -4765.59% | -1516.04% | -805.88% | Upgrade
|
| Free Cash Flow Margin | -6990.00% | -2274.89% | -1585.19% | -4478.57% | -1336.44% | -565.60% | Upgrade
|
| EBITDA | -252.86 | -191.9 | -139.03 | -104.2 | -66.08 | -45.64 | Upgrade
|
| D&A For EBITDA | 3.38 | 3.18 | 3.01 | 2.9 | 3.07 | 3.93 | Upgrade
|
| EBIT | -256.24 | -195.08 | -142.04 | -107.1 | -69.15 | -49.57 | Upgrade
|
| Revenue as Reported | 2.6 | 7.02 | 6.88 | 2.36 | 4.65 | 7.42 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.